Phytotherapeutical Methods Used by Traditional Healers of Eturnagaram Mandal, Warangal, Andhra Pradesh, India

The indigenous traditional practices of Koyas (Dorasattamu) of Tupakulagudem, Bhupathipuram and Devadula villages which are on the south of Godavari river, Eturnagaram mandal warangal District, Andhrapradesh, India are being here reported. They use different parts of medicinal plants for curing common ailments. The ethnomedicinal information includes 32 plant species, useful parts of plants and mode of administration

Predicting Consumers’ Ethical Behaviors Through Attitudes Toward Behavior and Prior Behavior

While the concerns for ethical issues relating to consumers have dramatically increased over the last decade, research investigating predictors of these behaviors has been sparse. This paper addresses the attitudinal, personal and cultural factors that predict a large majority of unethical behavioral practices of consumers. An empirical survey was conducted of consumers. The results show that consumer beliefs/values concerning the specific behaviors and their own past behaviors large predict the future behaviors. Consumers\u27 personal factors such as age, sex, nationality, individualism, etc. did not influence their ethical judgments and behaviors at all in this study of working adults

Effect of Co Doping on Structural and Magnetic Properties of ZnO Nanoparticles Synthesized by Novel Combustion Synthesis

ZnO is a wide band gap semiconductor (3.37 eV) with a high exciton binding energy (60 meV), which has wide applications in advanced optoelectronic devices. The theoretical prediction of room temperature ferromagnetism will be possible through the investigation of diluted magnetic semiconductors such as transition metal doped ZnO, especially Cobalt doped ZnO. The aim of the work is to synthesize Zn1 – xCoxO (x = 0 and x = 0.20) nanostructures through a novel urea based auto combustion method and its characterization. The Structural and Magnetic studies of the synthesized Zn1 – xCoxO Nano powders were carried out by X-Ray diffraction (XRD) technique and Vibrating Sample Magnetometer (VSM), respectively. When you are citing the document, use the following link http://essuir.sumdu.edu.ua/handle/123456789/3097

A study on Seed germination of Cassia alata Linn an antiallergenic plant

Cassia alata known as candle bush or Ringworm tree belongs to Cesalpinaceae family, which was found in diverse habitats in the tropics. C. alata leaves containing some chemical substances like chrysophanic acid, is a common ingredient in soaps, shampoos and lotions. The effectiveness of this plant against skin diseases is confirmed by modern scientific studies. The seed germination was gradually decreased by increasing the age of the seeds. Seed propagation is still used as a specialized tool for breeding purposes and for the propagation of pathogen-free plant material

Length-weight relationships for five fish species from Gulf of Mannar, southeast coast of India

The study documents length-weight relationships (LWRs) of five fish species viz. Chaetodon collare Bloch, 1787, Chaetodon octofasciatus Bloch, 1787, Pempheris mangula Cuvier, 1829, Pseudotriacanthus strigilifer (Cantor, 1849), and Rogadius asper (Cuvier, 1829) sampled from Gulf of Mannar, southeast coast of India. The fishes have been collected from bycatches of commercial trawlers from two landing centres of Gulf of Mannar during April, 2019 to March, 2020. The estimated co-efficient ‘b’ values ranged from 2.878 (Pseudotriacanthus strigilifer) to 3.146 (Chaetodon octofasciataus) and r2 values ranged from 0.953 (Chaetodon collare) to 0.989 (Pseudotriacanthus strigilifer). The results of LWR of five species show that these are highly significant (p < 0.05). Except Pseudotriacanthus strigilifer, the study is the first report of the LWRs of the four fish species which are not reported yet in FishBase

An approach to determine crystalline content of Granisetron in transdermal patches using X-ray diffraction technique

Granisetron is a drug used to treat nausea and vomiting after chemotherapy. Crystallization of drug is always a major concern in the transdermal drug delivery system. In view of consistent biopharmaceutical performance, monitoring and controlling the crystallization during product development and shelf life is very important. The need was felt to have an accurate method for determination of crystallinity in transdermal patches.The present study is about development and validation of a quantitative X-ray diffraction method for the determination of the extent of crystallization of the drug in transdermal formulation of Granisetron. Specimens of different physically spiked concentrations were carefully prepared accurately by weighing and distributing crystalline active pharmaceutical ingredient (API) onto placebo liner patches, pasted on Silicon low background sample holder (diameter of 24.5 mm, made up of Si crystal). All the specimens thus prepared were scanned using optimized instrumental parameters while enabling specimen rotation during the diffraction analysis to ensure homogeneous exposure to the incident X-rays. Using this novel approach, limit of detection

Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study

BACKGROUND & AIMS: The Drug-Induced Liver Injury Network is conducting a prospective study of patients with DILI in the United States. We present characteristics and subgroup analyses from the first 1257 patients enrolled in the study. METHODS: In an observational longitudinal study, we began collecting data on eligible individuals with suspected DILI in 2004, following them for 6 months or longer. Subjects were evaluated systematically for other etiologies, causes, and severity of DILI. RESULTS: Among 1257 enrolled subjects with suspected DILI, the causality was assessed in 1091 patients, and 899 were considered to have definite, highly likely, or probable DILI. Ten percent of patients died or underwent liver transplantation, and 17% had chronic liver injury. In the 89 patients (10%) with pre-existing liver disease, DILI appeared to be more severe than in those without (difference not statistically significant; P = .09) and mortality was significantly higher (16% vs 5.2%; P 365 days were nitrofurantoin (25%) or minocycline (17%). There were no differences in outcomes of patients with short vs long latency of DILI. Compared with individuals younger than 65 years, individuals 65 years or older (n = 149) were more likely to have cholestatic injury, although mortality and rate of liver transplantation did not differ. Nine patients (1%) had concomitant severe skin reactions; implicated agents were lamotrigine, azithromycin, carbamazepine, moxifloxacin, cephalexin, diclofenac, and nitrofurantoin. Four of these patients died. CONCLUSIONS: Mortality from DILI is significantly higher in individuals with pre-existing liver disease or concomitant severe skin reactions compared with patients without. Additional studies are needed to confirm the association between azithromycin and increased DILI in patients with chronic liver disease. Older age and short or long latencies are not associated with DILI mortality

A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer

Purpose This phase 1 study examined safety, pharmacokinetics (PK), and efficacy of the poly(ADP-ribose) polymerase (PARP) inhibitor ABT-767 in patients with advanced solid tumors and BRCA1/2 mutations or with high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. Methods Patients received ABT-767 monotherapy orally until disease progression or unacceptable toxicity. Dose was escalated from 20mg once daily to 500mg twice daily (BID). Dose-limiting toxicities, recommended phase 2 dose (RP2D), food effect, objective response rate, and biomarkers predicting response were determined. Results Ninety-three patients were treated with ABT-767; 80 had a primary diagnosis of ovarian cancer. ABT-767 demonstrated dose-proportional PK up to 500mg BID and half-life of 2h. Food had no effect on ABT-767 bioavailability. Most common grade 3/4 treatment-related adverse events were nausea, fatigue, decreased appetite, and anemia. Anemia showed dose-dependent increase. RP2D was 400mg BID. Objective response rate by RECIST 1.1 was 21% (17/80) in all evaluable patients and 20% (14/71) in evaluable patients with ovarian cancer. Response rate by RECIST 1.1 and/or CA-125 was 30% (24/80) in patients with ovarian cancer. Mutations in BRCA1 or BRCA2, homologous recombination deficiency (HRD), and platinum sensitivity were associated with tumor response. Median progression-free survival was longer for HRD positive (6.7months) versus HRD negative patients (1.8months) with ovarian cancer. Conclusions ABT-767 had an acceptable safety profile up to the established RP2D of 400mg BID and dose-proportional PK. Patients with BRCA1 or BRCA2 mutation, HRD positivity, and platinum sensitivity were more sensitive to ABT-767

A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer

Purpose This phase 1 study examined safety, pharmacokinetics (PK), and efficacy of the poly(ADP-ribose) polymerase (PARP) inhibitor ABT-767 in patients with advanced solid tumors and BRCA1/2 mutations or with high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. Methods Patients received ABT-767 monotherapy orally until disease progression or unacceptable toxicity. Dose was escalated from 20 mg once daily to 500 mg twice daily (BID). Dose-limiting toxicities, recommended phase 2 dose (RP2D), food effect, objective response rate, and biomarkers predicting response were determined. Results Ninety-three patients were treated with ABT-767; 80 had a primary diagnosis of ovarian cancer. ABT-767 demonstrated dose-proportional PK up to 500 mg BID and half-life of ~2 h. Food had no effect on ABT-767 bioavailability. Most common grade 3/4 treatment-related adverse events were nausea, fatigue, decreased appetite, and anemia. Anemia showed dose-dependent increase. RP2D was 400 mg BID. Objective response rate by RECIST 1.1 was 21% (17/80) in all evaluable patients and 20% (14/71) in evaluable patients with ovarian cancer. Response rate by RECIST 1.1 and/or CA-125 was 30% (24/80) in patients with ovarian cancer. Mutations in BRCA1 or BRCA2, homologous recombination deficiency (HRD), and platinum sensitivity were associated with tumor response. Median progression-free survival was longer for HRD positive (6.7 months) versus HRD negative patients (1.8 months) with ovarian cancer. Conclusions ABT-767 had an acceptable safety profile up to the established RP2D of 400 mg BID and dose-proportional PK. Patients with BRCA1 or BRCA2 mutation, HRD positivity, and platinum sensitivity were more sensitive to ABT-767